Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Net Cash Flow (2021 - 2025)

Verrica Pharmaceuticals has reported Net Cash Flow over the past 5 years, most recently at $9.0 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $9.0 million for Q4 2025, down 61.43% from a year ago — trailing twelve months through Dec 2025 was -$16.2 million (up 30.3% YoY), and the annual figure for FY2025 was -$16.2 million, up 30.3%.
  • Net Cash Flow for Q4 2025 was $9.0 million at Verrica Pharmaceuticals, up from $5.7 million in the prior quarter.
  • Over the last five years, Net Cash Flow for VRCA hit a ceiling of $34.7 million in Q1 2022 and a floor of -$20.6 million in Q1 2024.
  • Median Net Cash Flow over the past 5 years was -$4.8 million (2021), compared with a mean of $973050.0.
  • Peak annual rise in Net Cash Flow hit 325.11% in 2023, while the deepest fall reached 920.06% in 2023.
  • Verrica Pharmaceuticals' Net Cash Flow stood at -$4.7 million in 2021, then skyrocketed by 138.38% to $1.8 million in 2022, then tumbled by 920.06% to -$14.8 million in 2023, then surged by 258.32% to $23.4 million in 2024, then tumbled by 61.43% to $9.0 million in 2025.
  • The last three reported values for Net Cash Flow were $9.0 million (Q4 2025), $5.7 million (Q3 2025), and -$14.2 million (Q2 2025) per Business Quant data.